TREATMENT DATABASE

Nymalize (nimodipine) is a calcium channel blocker. Calcium channel blockers work by preventing calcium ions from entering smooth muscle cells. Calcium is especially important for the functioning of these cells and specialized cells in the heart. When calcium levels are lowered, the result is a relaxation of blood vessels, allowing an increased supply of blood and oxygen to the heart while decreasing its work load. As a consequence of their effect on blood vessels, calcium channel blockers are useful in treating cardiovascular disorders, such as angina (chest pain) and coronary artery disease, and to lower blood pressure. These drugs also may improve exercise capacity and subsequently reduce the need for surgery in patients with cardiac problems.

USES IN ME/CFS: At the 1990 CFIDS conference in Los Angeles, Dr. Ismael Mena presented evidence of cerebral dysfunction in patients with ME/CFS. Using neurological spectroscopic scanning techniques, Dr. Mena reported that 71% of ME/CFS patients have low blood flow (hypoperfusion) in the temporal lobe of the brain. He further reported that after treatment with calcium channel blockers, some of these patients exhibited clinically improved cerebral blood flow (CFIDS Chronicle, Spring/Summer 1990).

A number of ME/CFS clinicians have noted improvement in cognitive function in patients given calcium channel blockers. Dr. Jay Goldstein also observed improvements in cognitive function and energy level in patients given calcium channel blockers. He also noted increased exercise tolerance, decreased tender point sensitivity, and alleviation of panic disorder with nimodipine.

Treatment rating for Nymalize (nimodipine)